N-(4-((6-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)oxy)benzo[d]thiazol-2-yl)acetamide | 1124344-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(4-((6-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)oxy)benzo[d]thiazol-2-yl)acetamide
• CAS: 1124344-48-4
• 化学式: C₁₉H₁₁ClF₃N₅O₂S
• 分子量: 465.843
• InChiKey: ZRCVUIVSPHRPLN-UHFFFAOYSA-N

物化性质

• 密度：
  1.551±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.57
• 重原子数：
  31.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  89.89
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  N-(4-((6-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)oxy)benzo[d]thiazol-2-yl)acetamide 在 甲酸 、 palladium diacetate 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以68%的产率得到N-(4-(6-(6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide
  参考文献：
  名称：

  Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists

  摘要：

  Clinical candidate AMG 517 (1) is a potent antagonist toward multiple modes of activation of TRPV1; however, it suffers from poor solubility. Analogs with various substituents at the R region of 3 were prepared to improve the solubility while maintaining the potent TRPV1 activity of 1. Compounds were identified that maintained potency, had good pharmacokinetic properties, and improved solubility relative to 1. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.112
• 作为产物：
  描述：

  4-(6-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-amine 、 乙酸酐 在 吡啶 作用下， 生成 N-(4-((6-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)oxy)benzo[d]thiazol-2-yl)acetamide
  参考文献：
  名称：

  Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists

  摘要：

  Clinical candidate AMG 517 (1) is a potent antagonist toward multiple modes of activation of TRPV1; however, it suffers from poor solubility. Analogs with various substituents at the R region of 3 were prepared to improve the solubility while maintaining the potent TRPV1 activity of 1. Compounds were identified that maintained potency, had good pharmacokinetic properties, and improved solubility relative to 1. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.112